Skip to main content

IT Experts Newsletter – May edition: Does IT still need IT service catalogs?

Download PDF version here | Web view
logo
IT Experts
Software Technical Network Newsletter, May 2015
Dear Debabrata Banerjee,
HP's premier customer event, HP Discover, kicks off in Las Vegas, Nevada on June 2. I will be attending the event, on the lookout for IT Experts community members, networking with Vivit members and connecting with many of our valued partners. Are you interested in what Vivit is up to at HP Discover? Take a few minutes to read my blog article. If you are interested in a professional photo for your LinkedIn profile, please read this blog article from our Support, Services and Education team. Are you interested in exploring the world of DevOps at HP Discover? Get a complete view of DevOps at HP Discover. What about IT as a Service Broker? Read "It's time to disrupt IT! Meet the new Business of IT". Need more ideas? Spend some time searching the HP Discover Session catalog. See you at HP Discover!
Brian
Brian MacDonald
Senior Manager,
IT Experts Community
HP Software
Does IT still need IT service catalogs? Part 2: Standalone service catalogs
 
Let's examine some of the key concepts of the single IT service catalog.
     More     
WHITE PAPER: IT Service Catalog
VIDEO: HP Propel Service Catalog
Does IT still need IT service catalogs? Part 2: Standalone service catalogs
A closer look at the functionality of OMi Script Dev Kit
 
Operations Manager i is the tool of choice for your monitoring needs.
   More   
HP releases new advanced software support service with FlexCare
 
Designed to help and partner with you to get greater value from your HP Software products and solutions.
Read more
IT Central Station's "Top Testing Tools" ranking
 
HP LoadRunner and Quality Center go #1 and #2 in the ranking!
Learn more

Hot topics

BLOG: What will your IT portal be wearing this season?

TRIAL: Know the Health of Your Mobile App

REPORT: ArcSight's SIEM QuickPulse: How to Better Guard Against a Security Breach

PRODUCT REVIEW: ArcSight's Improving the Effectiveness of Log Analysis with HP ArcSight Logger 6

Fortify's HP Internet of Things Security Study: Home Security Systems Report

The Learning Center Notification

Hot topics

Events & webinars
HP Discover Las Vegas June 2-4
Engineers Assemble! Meet 7 heroic HP Support Engineers ready to save your day at Discover
HP SaaS Technical Webinar Series for HP ALM, QC and PC
Upcoming webinars
Vivit - your global, independent, HP Software community
Membership and participation is free
Registration is NOW OPEN! Vivit Deep Dive Sessions
What if you could have four hours to learn more about a specific topic from the thought leaders, evangelists, and technologists that are gathering inputs around the world and setting the direction with you? With the Vivit Deep Dive, you have the opportunity to join these experts and have a wonderful time as we put our thinking caps on, and quickly go through a deep dive discussion and hands-on exercises with the topics you care most about.

Sessions run on Monday, June 1, from 1:00 - 5:00 pm. Register for these sessions through your new and existing HP Discover conference registration. All sessions will be held at The Venetian on the 3rd and 4th floors. The cost per session is only $99 thanks to our sponsors—this is an incredible value which normally costs $495. Seating is limited, so be sure to register today! Learn more.
Get Charged with Vivit at HP Discover Las Vegas
Vivit Breakout Sessions at HP Discover Las Vegas
IT Experts
A peer-to-peer community where practitioners can participate in discussions, attend online events and read blogs about HP software.
Join us!
IT Leaders
Are you ready for BYOEverything?
The latest Discover Performance issue is all about specific steps to solve specific problems—from managing BYOEverything to creating single-pane views of ops. For complete articles and more news like this, see our June newsletter edition or visit http://www.hp.com/go/discoverperformance. Sign up now to get strategic insights and exclusive content for business leaders delivered to your inbox every other month.
Blogs
Big Data
LoadRunner/Performance Center
Security Products
Discussion Boards
Data Protection
Service Manager
Support Customer Forums
Connect
Twitter @HPSoftware
Facebook HP Software Solutions
   
If you have been forwarded this email and would like to join our mailing list click here to subscribe.

HP is committed to protecting your privacy. Your information will not be shared outside HP unless you give your consent. You can choose whether HP may communicate directly with you. For more information please see the HP Privacy Statement. As a valued contact or customer of HP, you are receiving this eNewsletter with information that we believe will be relevant to you. But if you do not wish to receive this communication in the future, please click here to unsubscribe.

© 1994-2015 Hewlett-Packard Company. All rights reserved. All product and company names referenced herein are trademarks of their respective owners. THIS DOCUMENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY. INFORMATION PROVIDED IN THIS DOCUMENT IS PROVIDED AS IS WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED. This document may be copied provided all text is included and copies contain HP's copyright notice and any other notices provided herein. Any pricing information provided in this newsletter represents estimated resale pricing. Actual reseller prices may vary.




Comments

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side